Durán-Prado Mario, Gahete Manuel D, Martínez-Fuentes Antonio J, Luque Raúl M, Quintero Ana, Webb Susan M, Benito-López Pedro, Leal Alfonso, Schulz Stefan, Gracia-Navarro F, Malagón María M, Castaño Justo P
Department of Cell Biology, Physiology, and Immunology, University of Córdoba, and Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición, E-14014 Córdoba Spain.
J Clin Endocrinol Metab. 2009 Jul;94(7):2634-43. doi: 10.1210/jc.2008-2564. Epub 2009 Apr 28.
Somatostatin and its related peptide cortistatin exert multiple actions on normal and tumoral tissue targets through a family of receptors termed somatostatin receptor (sst)1-5. Despite the considerable advances in the knowledge on these receptors and their (patho)physiological roles, there is still evidence that additional receptors for these peptides should exist to fully explain their actions.
The growing number of spliced variants found in similar receptor families, often present in tumors, and results from our group obtained on sst5 from other species (pig) led us to explore the existence of new human sst5 isoforms.
A rapid amplification of cDNA ends PCR approach on samples from a human pituitary tumor and a cell line enabled identification of two novel alternatively spliced sst5 receptor variants. The sequences obtained encode putative proteins that correspond to truncated isoforms of five and four transmembrane domains (TMDs), accordingly named sst5TMD5 and sst5TMD4, respectively. Both novel receptors show a differential expression pattern in normal tissues and are also present in pituitary tumors of diverse etiology including nonfunctioning adenomas, corticotropinomas, somatotropinomas, and a prolactinoma. In contrast to the predominant plasma membrane localization of full-length sst5, both sst5TMD5 and sst5TMD4 show a preferentially intracellular localization. Despite their truncated nature, both receptors are functional, as shown by their ability to mediate selective, ligand-induced rises in free cytosolic calcium concentration. Specifically, whereas sst5TMD5 is selectivity activated by somatostatin compared with cortistatin, cells transfected with sst5TMD4 almost exclusively respond to cortistatin and not to somatostatin.
Our results demonstrate the existence of two previously unidentified sst5 spliced variants with distinct distribution in normal tissues and pituitary tumors, unique ligand-selective signaling properties, and subcellular distribution, which could contribute to somatostatin and cortistatin signaling in normal and tumoral cells.
生长抑素及其相关肽可的生长抑素通过一类称为生长抑素受体(sst)1 - 5的受体对正常组织和肿瘤组织靶点发挥多种作用。尽管在这些受体及其(病理)生理作用的认识方面取得了相当大的进展,但仍有证据表明,这些肽应该存在其他受体才能充分解释其作用。
在相似受体家族中发现的剪接变体数量不断增加,这些变体常出现在肿瘤中,并且我们小组从其他物种(猪)的sst5获得的结果促使我们探索新的人类sst5亚型的存在。
对来自人垂体肿瘤和细胞系的样本进行cDNA末端快速扩增PCR方法,能够鉴定出两种新的选择性剪接的sst5受体变体。获得的序列编码推定的蛋白质,分别对应于五个和四个跨膜结构域(TMD)的截短亚型,因此分别命名为sst5TMD5和sst5TMD4。这两种新受体在正常组织中显示出不同的表达模式,并且也存在于多种病因的垂体肿瘤中,包括无功能腺瘤、促肾上腺皮质激素瘤、生长激素瘤和催乳素瘤。与全长sst5主要定位于质膜相反,sst5TMD5和sst5TMD4均显示出优先定位于细胞内。尽管它们是截短的性质,但两种受体都是有功能的,这通过它们介导选择性的、配体诱导的游离细胞质钙浓度升高的能力得以证明。具体而言,与可的生长抑素相比,sst5TMD5被生长抑素选择性激活,而转染了sst5TMD4的细胞几乎只对可的生长抑素反应,而对生长抑素无反应。
我们的结果证明存在两种先前未鉴定的sst5剪接变体,它们在正常组织和垂体肿瘤中具有不同的分布、独特的配体选择性信号特性和亚细胞分布,这可能有助于生长抑素和可的生长抑素在正常细胞和肿瘤细胞中的信号传导。